About the Report
Unit dose packaging is a type of primary packaging, which constitutes the first level of containers used for packaging of pharmaceutical products. These include blisters, vials, ampoules, and prefilled syringes cartridges. The increasing use of medications as a part of treatment prescribed for various ailments and for large vaccination programs undertaken by leading international organizations such as UNISEF, the World Health Organization (WHO), and others have been significantly fuelling the demand for pharmaceutical unit dose packaging solutions. Sales have been skyrocketing amid vaccination drives and treatment offered to contain COVID-19.
In its new study, ESOMAR-certified market research and consulting firm Future Market Insights (FMI) offers insights about key factors driving demand for pharmaceutical unit dose packaging. The report tracks the global sales of pharmaceutical unit dose packaging in 20+ high-growth markets, along with analyzing the impact COVID-19 has had on the pharmaceutical unit dose packaging industry.
How Historical Sales of Pharmaceutical Unit Dose Packaging Match Up with Future Outlook
The earliest attempts in unit dose dispensing were documented in the mid-60. Since then, in 1975 unit drug dose distribution was approved by board of directors in the American Society of Hospital Pharmacists (ASHP). Over the past decade, increasing investment by healthcare institutions and biopharmaceutical firms in research and development of new medications and increasing government investment healthcare sector have aggressively enhanced the demand for pharmaceutical unit dose packaging.
The demand for pharmaceutical unit dose packaging is expected to surge exceptionally with the roll-out of COVID-19 treatment programs in addition to the regular diseases precautions, & treatments across the globe. Besides this, consumers are largely inclined towards precautionary vaccination from the common diseases such as measles, polio, cancer, and many others, thus considerably rising the global demand for unit drug dose packaging consumption. According to the analysis, pharmaceutical unit dose packaging sales are likely tap double digit growth during the forecast period
Nowadays, pharmaceutical unit dose packaging formats such as blister, vials, pre-filled syringes carriages and ampoules are in high demand, particularly in vaccination intended to contain chronic ailments and more recently to fulfil COVID-19 treatment needs. Owing to the growing demand from pharmaceutical packaging solutions for high end drugs, medicines, and vaccines, the market is expected to grow during the pandemic period.
The increasing demand for these pharmaceutical products will enable the pharmaceutical unit dose packaging market reach US$ 26 billion by 2021. Increasing prevalence of infectious diseases such as influenza, hepatitis, Ebola, tuberculosis, swine flu, and others are driving the product development. These developments are indicative of a positive outlook for the market. Against this backdrop, the report forecasts the pharmaceutical unit dose packaging market to grow at 14.7% CAGR through 2031.
Convenience and Ease in Handling: Key Advantages of Pharmaceutical Unit Dose Packaging
Unit dose blisters, vials, and pre-filled syringes ensure accurate delivery of the drug. This in turn helps patients to self-administer the medicine without any prior training for the safe administration of drugs. Also, the use of single or unit pharmaceutical doses results in a decrease in the medication error such as reduced dosing and risk of microbial contamination. They also help in eliminating the risk multiple dosing of the drug.
Prefilled syringes can be disposed of easily compared to traditional syringes as the needle is drawn inside the barrel after use or it can be retractable. Furthermore, it also serves the additional advantage of having electronic documentation for easy monitoring and ease of identifying potentially damaged containers. Pharmaceutical unit dose packaging not only offers greater convenience to patients in administering the medicine, but it results in a reduction in unnecessary costs for the patient.
Market Research Methodology - Perfected through Years of Diligence
A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.
What is the Impact of Coronavirus Pandemic on Pharmaceutical Unit Dose Packaging Consumption?
The demand for vaccines was projected to reach 4.8 billion doses in 2019, according to the World Health Organization (WHO), which showcases an improvement by nearly 20 percent from last year, thanks to the increasing demand from the Asia and Africa markets. But the recent coronavirus pandemic have triggered the demand to record new as a result of the urgency of vaccination. Local government organizations and drug development companies across the globe are placing huge orders worth millions of dollars. This has been compelling the makers of blister, syringes and vials to add up production capacity.
The manufactures also are ramping up their production facilities for pharmaceutical unit dose packaging containers to fulfill the global needs.
- In July 2020, the Becton, Dickinson & Company partnered with U.S. Government on $70 Million manufacturing infrastructure project for Mass Vaccination Campaigns.
- Stevanato Group has received an order from the global nonprofit Coalition for Epidemic Preparedness Innovations (CEPI) for 100 million vials.
What is the Impact of Glass Fragility and Delamination on Pharmaceutical Unit Dose Packaging Sales?
The fragility of glass is one of the major concerns for manufacturers and consumers. Delamination of glass occurs from glass bits and surface degradation which is can be observed as chips within the medicinal products. Delamination is a serious problem because any foreign particle injected may be extremely hazardous for the patient.
Furthermore, long time span of storage and drug delivery might cause visible glass delamination, which can create enormous risks. In recent years, delamination in glass ampoules has led to frequent product recalls, patient safety issues, and economic losses. Product recalls in recent years have caused pharmaceutical companies severe economic losses, going into millions, primarily due to glass delamination.
According to the Corning Inc. “A glass supplier for the pharmaceutical industry, delamination, seemingly minor occurrence, can then have costly consequences. One, single recall can cost a pharma company US$ 250 Mn”
Hence, glass fragility and glass delamination are perceived as major risks in the pharmaceutical sector.
Sound Pharmaceutical Base Supports Growth in U.S.
According to the report, the United States is likely to exhibit consistent demand for pharmaceutical unit dose packaging products over the next five years. One of the key aspects supporting market growth is that, the U.S. is the place for most of the top pharmaceutical drugs & medications research and development and manufacturing facilities who specifically deal with new product developments for various diseases.
Johnson & Johnson, Pfizer Inc., AbbVie Inc., Eli Lilly and Company, and many others have their R&D and manufacturing facilities in the U.S. which plays an important role in fuelling sales of pharmaceutical unit dose packaging solutions.
On the other hand, the top suppliers of pharmaceutical unit dose packaging products such as West Pharmaceutical Services, Inc., Berry Global, Inc., Aptar Group, Inc., Becton, Dickinson & Company, and Catalent, Inc. are tirelessly supplying their services to the customers in the U.S.
What is Driving German Pharmaceutical Unit Dose Packaging Market?
The Federal Statistical Office Germany has reported that healthcare spending rose by 4% in 2018 from 2017 in Germany. In 2018, the country’s healthcare expenditure accounted for 11.7% of the GDP. Moreover, country’s projected healthcare spending exceeded US$ 505 bn in 2020, creating a conducive environment for the expansion of the pharmaceutical unit dose packaging market.
Also presence of large packaging manufacturing companies such as Gerresheimer AG., SCHOTT AG, SGD S.A., and Bormioli Pharma is continuously supporting the expansion in Germany.
- In 2020, SCHOTT AG delivers vials to pack 2 billion dosages of Coronavirus vaccines.
- In 2019, Gerresheimer AG opened a new plant for the production of pharmaceutical primary plastic packaging in China.
How Have Pharmaceutical Unit Dose Packaging Products Made Their Place in the U.K.?
Alzheimer’s and some other disease have long been in the U.K. for which the healthcare units and hospitals are using innovative and advanced methods for dispensing medications in pouches in the UK. The Alzheimer’s Research Trust states that the total of patients with dementia in the U.K. to be over 1.5 million in 2020. Healthcare units can form an important measure of the care strategy, helping the patients and nurses to manage medicines in a suitable way. Patients with other psychiatric illness such as schizophrenia also need critical care supplies.
Here comes the roles of pharmaceutical unit dose packaging solution that shows the gradient to fulfill the demand of these patients. Single or unit pharmaceutical drug doses results in a decrease in the medication error with reduction in the risk of microbial contamination. Also, convenience and ease in handling of these pharmaceutical unit dose packaging solution will help them in providing accurate and measured medications to the patients.
China’s Entrance to Vaccine Development Market
China is organizing to bring reasonable vaccines to the world that will follow all the standards for safety, quality and security. A few multinational organizations from the U.K. the U.S., and Germany have long controlled the global vaccine development and manufacturing industry. However some companies from China are now becoming key manufacturers of vaccines and have begun to sell these vaccines in the global market, competition is expected to rise and prices are set to fall.
- Recently in January 2021, Indonesia gave approval to China’s Sinovac Biotech's Covid-19 vaccine. Besides this, Malaysia Pharmaniaga Bhd has signed an agreement with China’s Sinovac to purchase 14 million doses of ready-to-fill COVID-19 vaccines.
At the Global Vaccine Summit in June 2020, China pledged a new US$ 20 million commitment to support GAVI’s strategic work for the 2021-2025 period, acknowledging the Alliance's vital work in supplying children around the world with life-saving vaccines.
Is India Showing Growth Prospects?
India’s epidemiological outline is changing, so demand is expected to increase for medicines and drugs for ailments affecting central nervous system, cardio vascular hitches, and other chronic infections.
Together these factors mean that India represents a promising market for global pharmaceutical manufacturers. More than that, India has a growing pharmaceutical industry of its own. It is likely to become a competitor of global pharmaceutical industry in some key areas, and a potential partner in others.
Increasing buying power and epidemiological changes should spur dramatic growth in sales volumes of medicines and drugs and thereby opening new opportunities for pharmaceutical unit dose packaging market players.
Opportunities Increasing for Prefilled Syringes Cartridges Sales
Mass vaccination programs would be significantly enhanced by having the vaccines previously filled in syringes cartridges, certainly the ones that do not need super low temperature. These solutions do not require high proficiency and training. Their sales are accelerated because they do not need scheduling the vaccine on the front line, possibly reducing interface time for the patient vaccinator. Driven by these factors, prefilled syringes cartridges segment is projected account for nearly 1/4th of the market share by 2031. Companies operating in the market are already capitalizing on this opportunity.
- As COVID-19 demand surges, Becton, Dickinson and Company plans $1.2 bn expansion to boost prefilled syringe output by 50%.
- Retractable Technologies signed two contracts with the U.S. government worth $138 million to supply syringes for a vaccine.
However, in the global pharmaceutical unit dose packaging market, blisters and vials are the most sought after product segments, globally preferred by consumers. Cumulatively these segments will continue accounting for over 3/5th of the global share among products through 2031. Blisters offer greater accuracy and upfront usage in the pills, capsules and tablets, which are the leading causes behind dominance of the segment across all the regions.
What is the Market Share of Glass Material?
By material, maximum number of manufactures prefer to make primary packaging from glass. This is because glass is non-reactive and will therefore not react with the inner contents. It’s clear and shiny appeal guarantees the purity of the drug. Due to these factors, the glass segment is anticipated to witness expansion at 4.9x times in the global pharmaceutical unit dose packaging market.
Besides this, in 2020 the segment have captured nearly 1/3rd of the total pharmaceutical unit dose packaging market share due to its multipurpose applications in the pharmaceutical packaging solutions.
How Big is the Opportunity in the Injectable End Uses?
By end use, the injectable segment is expected to dominate, accounting for more than 1/4th of the revenue share by 2031. Besides this, the segment is estimated to expand by five folds on the backdrop of rising consumption of vaccines and injectable drugs by the consumers across the globe.
Insecure injection exercises, including the wrong use of medications for more than one patient can cause serious drug safety concerns such as bacterial contaminations transferred between patients. To report confusion concerning the existing product terminology, the FDA is creating a new packaging type term “single-patient-use” product, to address the requisite for telling a package that contains injectable medical product that is intended to be used on a single patient. A pharmaceutical unit dose packaging is designed for use with a single patient as a single infusion using ampoules, vials, and prefilled syringes.
The global pharmaceutical unit dose packaging market is fragmented in nature, exhibiting the presence of many globally established and local players. In order to retain their competitive edge, leading players are offering products according to industry necessities.
Some of the companies operating in the pharmaceutical unit dose packaging market are aiming at strategic acquisition of new market entrants precisely who deal with sustainable pharmaceutical unit dose packaging products.
- In November 2020, Becton, Dickinson and Company acquired the Medical Business Assets of CUBEX LLC, broadening automated dispensing portfolio across Care Continuum.
- In January 2020, Sonoco acquired Thermoform Engineered Quality, LLC, and Plastique Holdings, LTD, (together TEQ), a global manufacturer of thermoformed packaging serving healthcare, medical device, and consumer markets.
Some of the leading companies operating in the market are:
- Gerresheimer AG
- West Pharmaceutical Services, Inc.
- Schott AG
- SGD SA
- Stevanato Group S.p.a.
- Klockner Pentaplast Group
- UDG Healthcare plc
- Amcor plc
- Berry Global, Inc.
- Comar LLC
- Constantia Flexibles Group GmbH
- Nipro Corporation
- Catalent, Inc.
- Becton, Dickinson and Company
- Adelphi Healthcare Packaging
- Winpak Ltd.
- Pacific Vial Manufacturing Inc.
- Sonoco Products Company
- WestRock Company
- AptarGroup, Inc.
(APAC/China based Players)
- Shanghai Tongpeng Electric Material Co., Ltd
- Tonbay Industry Co., Ltd.
- Borosil Limited
- Piramal Glass Private Limited
- Jinan Youlyy Industrial Co., Ltd
- SVM ENTERPRISES
- Khemka Glass
- Taj Pharma India
- Shandong Pharmaceutical Glass Co., Ltd.
- Avesta Continental Pack
*The list is not exhaustive, and only for representational purposes. Full competitive intelligence with SWOT analysis available in the report.
Scope of the Report
Historical Data Available for
US$ Billion for Value and Thousand Tons for Volume
Key Regions Covered
North America, Latin America, Europe, East Asia, South Asia, Oceania, and Middle East & Africa
Key Countries Covered
US, Canada, Germany, U.K., France, Italy, Spain, Poland, Russia, China, Japan, South Korea, India, Thailand, Malaysia, Vietnam, Indonesia, Australia, New Zealand, GCC Countries, Turkey, Northern Africa, South Africa
Key Segments Covered
Product, Material, End Use, and Region
Key Companies Profiled
(APAC/China based Players)
Market Forecast, Brand share analysis, Competition intelligence, DROT analysis, Market Dynamics and Challenges, Strategic Growth Initiatives
Customization & Pricing
Key Questions Answered in the Report
Which is the most lucrative market for pharmaceutical unit dose packaging?
Europe currently leads the global market for pharmaceutical unit dose packaging. Sales in Europe are expected to account for over 1/4th of total demand by 2021.
Which is the top-selling pharmaceutical unit dose product?
Vial is the most preferred pharmaceutical unit dose packaging product in the market. The demand for vial is expected to increase over the forecast period owing to their higher doses per vial capacity and non-reactiveness with the contents.
Who is the leading end user of pharmaceutical unit dose packaging?
As per FMI analysis, injectable and oral end use segments are expected to exhibit high demand, increasing the sales of pharmaceutical unit dose packaging.
Which are some of the leading companies offering pharmaceutical unit dose packaging?
Some of the leading companies offering pharmaceutical unit dose packaging are Gerresheimer AG, Stevanato Group, SCHOTT AG, Klockner Pentaplast Group, Pacific Vial Manufacturing Inc., Adelphi Healthcare Packaging, West Pharmaceutical Services, Inc. Nipro Corporation and among others.
Enquiry before Buying
- Is this research conducted by Future Market Insights?
Yes, the research has been conducted by expert analysts of Future Market Insights through a combination of primary research and secondary research. To know more about how the research was conducted, you can speak to research analyst
- What research methodology is followed by FMI?
FMI follows a methodology that encompasses demand side assessment of the market, and triangulates the same through supply side analysis. This methodology is based on use of standard market structure, methods and definitions. Request detailed methodology
- Who are the respondents for primary research?
FMI speaks to stakeholders across the spectrum, including C-level executives, distributors, product manufacturers, industry experts. For a full list of primary respondents, please reach out to us.
- What are the sources of secondary research?
FMI conducts extensive secondary research through proprietary databases, paid databases, and information available in the public domain. We refer to industry associations, company press releases, annual reports, investor presentations, and research papers. More information about desk research is available upon request.
- Is a sample of this report available for evaluation?
Yes, you can request a sample and it will be sent to you through an email.
- How can I buy this report?
FMI provides a secure online payment system to buy report seamlessly. You can buy the report securely and safely.
Pharmaceutical unit dose packaging Market by Category
- Blisters Pharmaceutical Unit Dose Packaging
- Ampoules Pharmaceutical Unit Dose Packaging
- Vials Pharmaceutical Unit Dose Packaging
- Prefilled Syringes Cartridges
- Plastic Pharmaceutical Unit Dose Packaging
- Aluminum Pharmaceutical Unit Dose Packaging
- Glass Pharmaceutical Unit Dose Packaging
- Paper & Paperboard Pharmaceutical Unit Dose Packaging
- Wound Care
- Respiratory Therapy
- North America
- Latin America
- Middle East and Africa (MEA)
- East Asia
- South Asia